Clinical significance of HPV test

Česká verzia

Authors: doc. MUDr. Pavel Freitag, CSc.
Authors place of work: 1. LF UK a VFN, Praha ; Gynekologicko-porodnická klinika
Published in the journal: Prakt Gyn 2006; 10(2): 71-73

Summary

Possible clinical role of HPV test is discussed in accordance with clinical course of HPV infection. Its main role as the supplementary test is in triage of equivocal cytological findings (ASC-US). Other possible applications in primary screening, in glandular laesions and in further indications are presented.

Key words:
HPV test – carcinoma of uterine cervix – screening

Zdroje

1. Muñoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.

2. American College of Obstetricians and Gynecologists. Human Papillomavirus. ACOG Practice Bulletin 2005; 61. (???opraveno: ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol. 2005 Apr;105(4):905-18.)

3. Cuzick J, Sasieni P, Davies P at al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999; 3: 1-196.

4. Herrero R, Hildesheim A, Bratti C et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92(6): 464-474.

5. Moscicki AB. Cervical cytology screening in teens. Curr Womens Health Rep 2003; 3: 433-437.

6. Monsonego J, Bosch FX, Cuorsaget P et al. Cervical cancer control priorities and new directions. Int J Cancer 2004; 108: 309-333.

7. Schneider A, Hoyer H, Lota B et al. Screening for high-grade cervical intraepithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529-534.

8. Schiffman M, Khan MJ, Solomon D et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97(2):147-150.

9. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327(18): 1272-1278.

10. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127(8): 959-968.

11. Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.

12. Wright TC jr, Cox JT, Massad LS et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-2129.

13. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-1392.

14. Clavel C, Cucherousset J, Lorenzato M et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical laesions. Br J Cancer 2004; 90: 1803-1808.

15. Wright TC jr, Schiffman M, Solomon D et al. Interim guidance on the use of HPV DNA testing as an adjunct to cervical cytology. Obstet Gynecol 2004; 103: 304-309.

16. Denny L, Kuhn L, Pollack A et al. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89: 826-833.

17. Zielinski GD, Bais AG, Helmerhorst TJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004; 59: 543-553.

18. Ronnett BM, Manos MM, Ransley JE et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Human Pathol 1999; 30(7): 816-825.